초록

The present invention provides a therapeutic drug for diabetes containing 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine (DOPE) as an active ingredient, particularly a therapeutic drug for diabetes that exhibits a GLUT4 endocytosis suppressive action by suppressing activation of PKCα and the like.

대표청구항 ▼

1.-8. (canceled) 9. A treatment method of diabetes, comprising administering an effective amount of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine to a subject in need thereof. 10. The method according to claim 9, comprising suppressing GLUT4 endocytosis. 11. The method according to claim 10, wherein

1.-8. (canceled) 9. A treatment method of diabetes, comprising administering an effective amount of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine to a subject in need thereof. 10. The method according to claim 9, comprising suppressing GLUT4 endocytosis. 11. The method according to claim 10, wherein suppression of GLUT4 endocytosis is caused by suppressing PKCα activation. 12. A method of suppressing GLUT4 endocytosis, comprising treating a cell with 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine. 13. The method according to claim 12, wherein suppression of GLUT4 endocytosis is caused by suppressing PKCα activation. 14. A method of treating metabolic syndrome, comprising administering an effective amount of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine to a subject in need thereof. 15. The method according to claim 9, wherein diabetes is type 2 diabetes.